Clinical Trial Detail

NCT ID NCT04089904
Title Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

gastric adenocarcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.